Dry Eye Syndrome - Drug Pipeline Landscape, 2023

Dry Eye Syndrome - Drug Pipeline Landscape, 2023

Dry eye syndrome (DES) is a condition that occurs when the eyes do not produce enough tears, or when the tears are of poor quality. This can lead to symptoms such as burning, itching, redness, and a feeling of grittiness or sandiness in the eyes. DES is a very common condition, affecting up to 30% of the population. It is more common in women than men, and the risk increases with age.

Dry eye syndrome ( keratoconjunctivitis sicca) is a chronic progressive condition due to lack of moisture and lubrication, resulting in constant irritation of the surface of the eye.

Dry eyes are caused many reasons that disrupt the healthy tear film. Reasons for tear film dysfunction are include hormone changes, autoimmune disease, inflamed eyelid glands or allergic eye disease. Decreased tear production and increased tear evaporation can also be the cause of dry eye.

Dry eye syndrome signs and symptoms include a stinging, burning or scratchy sensation, sensitivity to light

eye redness, sensation of having something in your eyes, difficulty wearing contact lenses, difficulty with night-time driving and blurred vision or eye fatigue.

Diagnostic tests and procedures used to determine the cause of your dry eyes include a comprehensive eye exam, a test to measure the volume of your tears, phenol red thread test, a test to determine the quality of your tears and a tear osmolarity test.

Dry eye syndrome treatment include medications reducing  eyelid inflammation, to control cornea inflammation, tear-stimulating drugs, and other procedures.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Dry Eye Syndrome treatment such as NOV03, BRM 421, RGN-259, branebrutinib, and others. Key players involved in the development of therapies to treat Dry Eye Syndrome are AstraZeneca, Bristol-Myers, AbbVie, Novartis, and others. 2 drugs are under pre-registration, 10+ drugs are in Phase III clinical trials and 35+ drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development. In Sep 2022, Novaliq announced that US FDA accepted the NDA filing for NOV03.

Report Highlights

Global Insight Service's, Dry Eye Syndrome - Drug Pipeline Landscape, 2023 report provides an overview of the Dry Eye Syndrome pipeline drugs. This report covers detailed insights on Dry Eye Syndrome drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Dry Eye Syndrome pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.